• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Bayer (XTRA:BAYN) Undervalued After Fresh Lynkuet And Nubeqa Trial Data?

    Simply Wall St·10/27/2026 04:38:39
    Listen to the news

    Bayer (XTRA:BAYN) drew investor attention after fresh clinical data on Lynkuet for menopausal sleep disturbance and Nubeqa in high risk prostate cancer highlighted new readouts from its pharmaceuticals pipeline and oncology portfolio.

    Bayer’s latest Lynkuet and Nubeqa data hit the market as the share price sits at €45.56, with a 1-day share price return of 3.59% and year to date share price return of 19.89%. The 1-year total shareholder return of 65.49% points to strong longer term momentum, despite a 30-day share price return that declined 8.92% and a 90-day share price return that eased 3.13%.

    Scan Bayer peers in pharma and healthcare that also show active pipelines and fresh clinical catalysts by reviewing the curated 123 healthcare AI stocks alongside this latest Lynkuet and Nubeqa data.

    The fresh rally leaves Bayer trading well below both analyst targets and intrinsic estimates. Is that discount a genuine margin of safety, or just a gap that recent enthusiasm has not yet closed?

    Most Popular Narrative: 22% Undervalued

    Against Bayer’s last close at €45.56, the most followed narrative points to a fair value of €58.22, which implies a sizeable valuation gap built on execution of specific operating plans rather than vague optimism.

    The main thing that has to go right is that Bayer converts its Crop Science and pharma programs, including the 2024–2029 efficiency framework and the AI and data driven R&D engine, into higher quality earnings and sustained free cash flow while containing litigation and capital spending pressures.

    See why 161 investors see Bayer as 22% undervalued.

    Result: Fair Value of €58.22 (UNDERVALUED)

    Still, heavy litigation payouts and large capital projects, such as the planned US$2.2b Ohio campus, could keep Bayer’s cash generation and balance sheet repair under pressure.

    Find out about the key risks to this Bayer narrative.

    Next Steps

    If this read leaves you weighing both caution and optimism, move quickly from headline impressions to your own assessment by reviewing the 4 key rewards.

    Looking for more Bayer investment ideas?

    If Bayer has sharpened your focus, do not stop here. Use curated stock lists to pressure test your thinking and uncover fresh opportunities before others move.